Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Nov;16(11):661.
doi: 10.1038/s41584-020-0493-2.

Safety and efficacy of HSCT for systemic sclerosis across clinical trials

Lynette Keyes-Elstein  1 , Erica Brittain  2 , Ashley Pinckney  1 , Ellen A Goldmuntz  2 , Keith M Sullivan  3
Affiliations
Comment

Safety and efficacy of HSCT for systemic sclerosis across clinical trials

Lynette Keyes-Elstein et al. Nat Rev Rheumatol. 2020 Nov.
No abstract available

PubMed Disclaimer

Comment on

  • Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
    Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE; SCOT Study Investigators. Sullivan KM, et al. N Engl J Med. 2018 Jan 4;378(1):35-47. doi: 10.1056/nejmoa1703327. N Engl J Med. 2018. PMID: 29298160 Free PMC article. Clinical Trial.
  • Systemic sclerosis: Autologous HSCT is efficacious, but can we make it safer?
    Burt RK, Farge D. Burt RK, et al. Nat Rev Rheumatol. 2018 Apr;14(4):189-191. doi: 10.1038/nrrheum.2018.34. Epub 2018 Mar 8. Nat Rev Rheumatol. 2018. PMID: 29515186 No abstract available.

References

    1. Burt, R. K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378, 498–506 (2011). - DOI
    1. van Laar, J. M. et al. Autologous hematopoietic stem cell transplantation versus intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311, 2490–2498 (2014). - DOI
    1. Sullivan, K. M. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N. Engl. J. Med. 378, 35–47 (2018). - DOI
    1. Burt, R. K. & Farge, D. Systemic sclerosis: autologous HSCT is efficacious, but can we make it safer? Nat. Rev. Rheumatol. 14, 189–191 (2018). - DOI
    1. Burt, R. K. et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 381, 1116–1124 (2013). - DOI

MeSH terms

LinkOut - more resources